New CEO and Chairman of the Board at Betagenon
Betagenon AB, a Sweden-based company focused on developing AMPK activator compounds, announced that James Hall BM, BCh, D.Phil has joined as CEO.
News
Xerum assigned by Swedish Public Health Agency to measure number of Swedes with antibodies against SARS-CoV-2
Umeå-based Xerum launched a home testing kit in March that detects antibodies against SARS-CoV-2 – the virus that causes Covid-19. Uptake of the kits was strong, and now the company has been given an important assignment by Sweden’s Folkhälsomyndigheten (the Swedish Public Health Agency).
“This is amazing news”, says Julia Wigren Byström, CEO of Xerum. “We will be responsible for the distribution and analysis of our self-sampling kits as part of a large study being conducted by the Swedish Public Health Agency to measure the number of people in the country who have developed antibodies”.
Lipum raises SEK 85 million and become listed on Nasdaq First North
Umeå-based biopharmaceutical company Lipum has been working towards a stock exchange listing since 2018 – and now the moment has finally arrived.
On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq’s opening bell, which has been specially transported to Umeå, to mark the occasion.
QureTech Bio expands workforce following major investment
Umeå-based pharmaceutical development company QureTech Bio is hiring more people as it intensifies its work to combat antibiotic resistance.
“We recently received a major investment which has created long-term security in the company. With more people in place, we can now really push on and look to the future”, says Helén Fält, who was recently appointed the new CEO of QureTech Bio.
Affärscoach på UBI – ett flexibelt och peppande jobb
Helén Fält har jobbat som affärscoach på Umeå Biotech Incubator i åtta år. I den rollen är hon ett viktigt bollplank till tidiga startups inom life science.
– Det är ett väldigt varierande, roligt och flexibelt jobb. Det är kul att få hänga med bolagen på deras tidiga resa och att göra det tillsammans med hela teamet på UBI, säger Helén Fält.
Umeå Biotech Incubator named Europe’s most innovative biotechnology incubator
Global Health and Pharma Magazine has named Umeå Biotech Incubator (UBI) as Europe’s most innovative biotechnology incubator in recognition of the positive changes it is making to the biotech industry.
“We are delighted to have been given this award, and that word of our innovative way of working has spread from Umeå to the whole of Europe. It’s really cool”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Nordic Biomarker moves to new premises – creates fantastic growth opportunities
Nordic Biomarker is now moving to new, larger premises in Umestan. The premises are four times as large as the previous one and provide good opportunities for the company to continue growing.
Lipum plans to list on Nasdaq First North Growth Market in spring of 2021
Umeå-based biopharmaceutical company Lipum AB is raising capital for a listing on the Nasdaq First North Growth Market in the spring of 2021.
“We are taking the next exciting step in the company’s development”, says Lipum’s CEO Einar Pontén.
Marina Norberg new CFO at Lipum AB
Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO).
Umeå technology companies back young enterprise initiative to get more women into tech industry
Three high school girls from Umeå have started a UF (Young Enterprise) company that hopes to encourage more girls to study technology and qualify to work in the tech industry.
The three students have already attracted the attention of a number of large technology companies in Umeå who share their ambition.
“We are delighted that several major technology companies believe in us. It shows they are willing to make an effort to create a gender-equal technology industry”, says Aja Tomic, one of the three UF company founders.
Urban Paulsson new Chairman of the Board of Lipigon Pharmaceuticals
Lipigon Pharmaceuticals AB, which develops new treatments for lipid-related diseases, announces that the board has elected Urban Paulsson as the new chairman of the board. Paulsson was elected to the board on October 30, 2020 and now replaces Carina Schmidt, who requested her own resignation from the board.
InfiCure Bio secures US patent and publishes new data in a top scientific journal
Inficure Bio, based in Umeå in northern Sweden, has recently been granted a patent in the United States for its unique preclinical model. At the same time a study describing the basics of the model has been accepted for publication in respected online journal Scientific Reports.
“We are delighted and anticipate that thanks to this attention we will strengthen our position in the market and expect even more customers to show interest in our model”, says Sofia Mayans, CEO of Inficure Bio.
New AI solution being tested at Umeå vaccine facility
A new AI solution for sustainable production is to be tested at Diamyd Medical’s vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden.
“This represents a unique opportunity that we do not see that often in Sweden. We are happy to be working with recognised experts in both AI and sustainable production”, says Ulf Hannelius, CEO of Diamyd Medical.
Create a circular business model with EEN and RISE
Give your company’s sustainability effort a boost! Sign up for three effective workshops on circular entrepreneurship.
Life Science Experts Join Umeå Biotech Incubator Board
Umeå Biotech Incubator (UBI) has strengthened its board with the appointment of respected business profiles Anette Nordvall, named Sweden’s most powerful tech investor by DI Digital, and Camilla Huse Bondesson, who has extensive experience of marketing, sales and business development in the life science industry.
“We have been focused on finding people who can contribute with business acumen and an investor perspective so that we continue building a world-class incubator”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Lipigon Pharmaceuticals strengthens the board with Urban Paulsson
At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson’s business law expertise entails a strengthening of the Board and is an important component for the company’s continued successful development.
Umeå-based Inficure Bio chosen for major national investor event
Umeå-based life science company Inficure Bio is one of three companies from northern Sweden chosen to present their business cases at ‘Mötesplats Stockholm – The Great Northern Capital Connect’ in early 2021.
Prediktera from Umeå named one of Europe’s hottest AI startups
Prediktera from Umeå in northern Sweden has made the list of Europe’s most dynamic Artificial Intelligence (AI) startups.
“This increases our visibility and opportunities to find partners, employees and customers in Europe and around the world,” says Andreas Vidman, CEO of Prediktera.
Umeå Biotech Incubator is co-organising international investor meeting
Umeå Biotech Incubator (UBI) is one of the hosts of the Swedish Life Science Investor Meeting (24-25th November), a digital event that will bring biotech companies and potential international investors together.
“The COVID-19 pandemic has caused untold problems for businesses, but one advantage it has given life science companies is the opportunity to meet international investors who may not have necessarily visited Sweden otherwise. Thanks to digital technology we can now reach out further than ever before”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Umeå researcher wants to save millions of lives with new antibiotics
Fredrik Almqvist, CEO of QureTech Bio based in Umeå in northern Sweden, is among thousands of researchers hoping to draw attention to the challenges of antibiotic resistance as part of World Antibiotic Awareness Week (18-24 November).
“It’s a problem that’s comparable to the climate crisis. We have to find new ways to kill antibiotic resistant disease-causing bacteria so we can save millions of lives every year,” he says.
